Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Kedrion IVIG 10% in Primary Immunodeficiency
NCT01581593Phase 3Completed
- Sponsor
- Kedrion Biopharma
- Start
- Nov 2012
- Primary completion
- Aug 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of immune globulin intravenous (human) in primary immunodeficiency (PI), sponsored by Kedrion Biopharma. Primary endpoint: Incidence of Acute, Serious Bacterial Infections at 13 months. Started Nov 2012; status: completed.
02
Drugs
immune globulin intravenous (human)
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT01581593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01581593.